{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:35Z","timestamp":1786987535410,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007088","name":"Uniwersytet Jagiello\u0144ski w Krakowie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.critrevonc.2024.104428","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T17:43:52Z","timestamp":1720028632000},"page":"104428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"201","author":[{"given":"Anita","family":"Sto\u017cek-Tutro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Reczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104428_bib1","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2019-126570","article-title":"Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial","volume":"134","author":"Al-Sawaf","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib2","first-page":"66","article-title":"Venetoclax-obinutuzumab modulates clonal growth: results of a population-based minimal residual disease model from the randomized CLL14 study","volume":"64","author":"Al-Sawaf","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib3","doi-asserted-by":"crossref","DOI":"10.7326\/ACPJC-2016-164-8-044","article-title":"Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia","volume":"164","author":"Aronson","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2024.104428_bib4","unstructured":"AstraZeneca, 2019. A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia - CSR.."},{"key":"10.1016\/j.critrevonc.2024.104428_bib5","first-page":"16","article-title":"Ibrutinib versus chlorambucil in patients 65 years and older with treatment-Naive CLL\/SLL (RESONATE-2TM): an international randomized phase 3 study","volume":"15","author":"Burger","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2024.104428_bib6","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.clml.2016.07.065","article-title":"Phase 3 Study of Ibrutinib versus Chlorambucil in Patients \u226565 Years with Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"16","author":"Burger","year":"2016","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2024.104428_bib7","doi-asserted-by":"crossref","unstructured":"Burger J., Tedeschi A., Barr P.M., 2016b. International, randomized phase 3 study results: ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2) 6. \u3008http:\/\/dx.doi.org\/10.1159\/000449050\u3009.","DOI":"10.1159\/000449050"},{"key":"10.1016\/j.critrevonc.2024.104428_bib8","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104428_bib9","first-page":"506","article-title":"Oncology Nursing Experience in Phase 3 iLLUMINATE: First-Line Ibrutinib-Obinutuzumab Versus Chlorambucil-Obinutuzumab for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"10","author":"Burtt","year":"2019","journal-title":"J. Oncol. Navig. Surviv."},{"key":"10.1016\/j.critrevonc.2024.104428_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.HS9.0000845432.57626.72","article-title":"P637: FRONTLINE THERAPY CLL WITHOUT 17P DEL\/P53 ABERRATIONS: SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS","volume":"6","author":"Carid\u00e0","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2024.104428_bib11","article-title":"Efficacy of first-line treatment for chronic lymphocytic leukemia: A Bayesian network meta-analysis","volume":"40","author":"Chanan-Khan","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2024.104428_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102307","article-title":"Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY","volume":"65","author":"Chatzikonstantinou","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2024.104428_bib13","unstructured":"ClinicalTrials.gov, 2023a. Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia - NCT02242942 [WWW Document]. URL \u3008https:\/\/clinicaltrials.gov\/study\/NCT02242942\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib14","unstructured":"ClinicalTrials.gov, 2023b. Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na\u00efve CLL (ElevateTN) - NCT02475681 [WWW Document]. URL \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02475681\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib15","unstructured":"ClinicalTrials.gov, 2022. A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL) (GLOW) - NCT03462719 [WWW Document]. URL \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03462719\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib16","unstructured":"ClinicalTrials.gov, 2019a. Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1) - NCT00748189 [WWW Document]. URL \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT00748189\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib17","unstructured":"ClinicalTrials.gov, 2019b. A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na\u00efve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - NCT02264574 [WWW Document]. URL \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT02264574?tab=results\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib18","unstructured":"ClinicalTrials.gov, 2018a. CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) - NCT01010061 [WWW Document]. URL \u3008https:\/\/clinicaltrials.gov\/study\/NCT01010061?tab=results\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib19","unstructured":"ClinicalTrials.gov, 2018b. CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) - NCT02053610 [WWW Document]. URL \u3008https:\/\/clinicaltrials.gov\/study\/NCT02053610?term=cll11&page=3&rank=22\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib20","unstructured":"ClinicalTrials.gov, 2018c. CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) - NCT01998880 [WWW Document]. URL \u3008https:\/\/clinicaltrials.gov\/study\/NCT01998880?term=cll11&page=3&rank=23\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib21","unstructured":"ClinicalTrials.gov, 2017. Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL - NCT01722487 [WWW Document]. URL \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01722487\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib22","unstructured":"ClinicalTrials.gov, 2015. A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) - NCT01056510 [WWW Document]. URL \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01056510\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib23","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.3324\/haematol.2017.175380","article-title":"Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"103","author":"Coutre","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104428_bib24","unstructured":"Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, 2023. robvis - a web app designed to for visualizing risk-of-bias assessments performed as part of a systematic review."},{"key":"10.1016\/j.critrevonc.2024.104428_bib25","unstructured":"Dias, S., Welton, N., Sutton, A., Ades, A., 2011. NICE DSU technical support document 2: a generalised linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials [WWW Document]. URL \u3008https:\/\/www.sheffield.ac.uk\/media\/34176\/download?attachment\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104428_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib28","unstructured":"EMA, 2024a. Summary of Product Characteristics - Venclyxto [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib29","unstructured":"EMA, 2024b. Summary of Product Characteristics - Brukinsa [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brukinsa-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib30","unstructured":"EMA, 2023a. Summary of Product Characteristics - Imbruvica [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/documents\/product-information\/imbruvica-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib31","unstructured":"EMA, 2023b. Summary of Product Characteristics - Calquence [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/calquence-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib32","unstructured":"EMA, 2022a. Assessment report - Imbruvica [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/imbruvica-h-c-003791-ii-0070-epar-assessment-report-variation_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib33","unstructured":"EMA, 2022d. Assessment report - Brukinsa [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/brukinsa-h-c-004978-ii-0003-epar-assessment-report-variation_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib34","unstructured":"EMA, 2020a. Assessment report - Venclyxto [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/venclyxto-h-c-4106-ii-0023-g-epar-assessment-report-variation_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib35","unstructured":"EMA, 2020b. Assessment report - Calquence [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/calquence-epar-public-assessment-report_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib36","unstructured":"EMA, 2019b. Assessment report - Imbruvica [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/imbruvica-h-c-3791-ii-0047-epar-assessment-report-variation_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib37","unstructured":"EMA, 2016c. Assessment report - Imbruvica [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/imbruvica-h-c-3791-ii-00016-epar-assessment-report-variation_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib38","unstructured":"EMA, 2014a. Assessment report - Gazyvaro [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/gazyvaro-epar-public-assessment-report_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib39","unstructured":"EMA, 2014b. Assessment report - Arzerra [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/arzerra-h-c-1131-ii-0023-epar-assessment-report-variation_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib40","unstructured":"E.U. Clinical Trials Register, 2020. A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlorambucil in Combination with Obinutuzumab in Subjects with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [WWW Document]. URL \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-002069-31\/results\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib41","unstructured":"EU Clinical Trials Register, 2019a. A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199\/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions - 2014-001810-24 [WWW Document]. URL \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/download\/result\/zip\/pdf\/2014-001810-24\/1\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib42","unstructured":"E.U. Clinical Trials Register, 2019b. A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia - 2008-004932-19 [WWW Document]. URL \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/download\/result\/zip\/pdf\/2008-004932-19\/2\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib43","unstructured":"E.U. Clinical Trials Register, 2018. An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities. [WWW Document]. URL \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/download\/result\/zip\/pdf\/2009-012476-28\/1\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib44","unstructured":"E.U. Clinical Trials Register, 2016a. A Randomized Phase IIIb Study of Rituximab Added to a Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia (2009-012072-28) [WWW Document]. URL \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/download\/result\/zip\/pdf\/2009-012072-28\/1\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib45","unstructured":"E.U. Clinical Trials Register, 2016b. A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATETM-2) [WWW Document]. URL \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/download\/result\/zip\/pdf\/2012-003967-23\/1\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib46","article-title":"Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD-) in previously untreated patients (pts) with chronic lymphocytic","volume":"7052","author":"Fischer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib47","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104428_bib48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hon.52_2629","article-title":"Fixed-Duration Venetoclax Plus Obinutuzumab Improves Pfs and Minimal Residual Disease Negativity in Patients with Previously Untreated Cll and Comorbidities","volume":"37","author":"Fischer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib49","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/cancers15051504","article-title":"Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities","volume":"15","author":"Frustaci","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104428_bib50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.HS9.0000845532.14560.fe","article-title":"P662: Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (br) in patients with treatment-na\u00efve (tn) cll\/sll","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2024.104428_bib51","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104428_bib52","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib53","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104428_bib54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood.V122.21.528.528","article-title":"Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)","volume":"122","author":"Hillmen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib55","article-title":"Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatment-naive (TN) CLL\/SLL (RESONATE-2TM)","volume":"7","author":"Hillmen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5603\/HCP.2021.0001","article-title":"Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021","volume":"12","author":"Hus","year":"2021","journal-title":"Hematol. Clin. Pract."},{"key":"10.1016\/j.critrevonc.2024.104428_bib57","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.17219\/acem\/99911","article-title":"Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG)","volume":"28","author":"Iskierka-Ja\u017cd\u017cewska","year":"2019","journal-title":"Adv. Clin. Exp. Med"},{"key":"10.1016\/j.critrevonc.2024.104428_bib58","first-page":"S269","article-title":"CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/ SLL)","volume":"22","author":"Kahl","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk., Proc. Soc. Hematol. Oncol. 2022 Annu. Meet."},{"key":"10.1016\/j.critrevonc.2024.104428_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041018","article-title":"A History of Targeted Therapy Development and Progress in Novel\u2013Novel Combinations for Chronic Lymphocytic Leukemia (CLL)","volume":"15","author":"Karr","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104428_bib60","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2024.104428_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2024.104428_bib62","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood.V120.21.2744.2744","article-title":"Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe)","volume":"120","author":"Leblond","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat. Comput."},{"key":"10.1016\/j.critrevonc.2024.104428_bib65","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3324\/haematol.2017.170480","article-title":"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104428_bib66","first-page":"149","article-title":"Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study","volume":"56","author":"Michallet","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2024.104428_bib67","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13943","article-title":"The net clinical benefit of targeted agents in the upfront treatment of elderly\/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis","volume":"110","author":"Molica","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7365\/JHPOR.2018.1.3","article-title":"Treatment options in chronic lymphocytic leukemia (CLL) \u2013 a Polish perspective","author":"Monica","year":"2018","journal-title":"J. Health Policy Outcomes Res."},{"key":"10.1016\/j.critrevonc.2024.104428_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib70","first-page":"95","article-title":"SEQUOIA: results of a Phase 3 Randomised Study of Zanubrutinib versus Bendamustine + Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukaemia\/Small Lymphocytic Lymphoma","author":"Munir","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib71","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2021-148666","article-title":"First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: the Glow Study","author":"Munir","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib72","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S2152-2650(22)01322-2","article-title":"First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study","volume":"22","author":"Munir","year":"2022","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2024.104428_bib73","first-page":"28","article-title":"ELEVATE-TN: a phase 3, multicentre, open-label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Clb) in patients (pts) with treatment-naive chronic lymphocytic leukaemia (TN-CLL)","volume":"26","author":"Munir","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib74","unstructured":"NA, 2022. SEQUOIA: results of a Phase 3 Randomized Study of Zanubrutinib vs Bendamustine + Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Clinical advances in hematology & oncology 20, 12\u201313. https:\/\/doi.org\/NA."},{"key":"10.1016\/j.critrevonc.2024.104428_bib75","unstructured":"National Cancer Institute, 2023. Cancer Stat Facts: NHL \u2014 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) [WWW Document]. URL \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/cllsll.html\u3009."},{"key":"10.1016\/j.critrevonc.2024.104428_bib76","unstructured":"NCCN Clinical Practice Guidelines in Oncology, 2023. Chronic Lymphocytic Leukemia\/ Small Lymphocytic Lymphoma. Version 1.2024."},{"key":"10.1016\/j.critrevonc.2024.104428_bib77","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2024.104428_bib78","doi-asserted-by":"crossref","first-page":"12423","DOI":"10.1182\/blood-2022-156499","article-title":"Systematic Review and Network Meta-Analysis of Frontline Targeted Therapy in Chronic Lymphocytic Leukemia Shows Comparable Efficacy but Distinct Toxicity","volume":"140","author":"Pearson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib79","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.3390\/ijms24129930","article-title":"Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials","volume":"24","author":"Rizzuto","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104428_bib80","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib81","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2024.104428_bib82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2019-128404","article-title":"ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)","volume":"134","author":"Sharman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib83","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104428_bib84","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ 366"},{"key":"10.1016\/j.critrevonc.2024.104428_bib85","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104428_bib86","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood-2021-148457","article-title":"SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"138","author":"Tam","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib87","article-title":"Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive CLL\/SLL (resonate-2TM)","volume":"495","author":"Tedeschi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104428_bib88","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104428_bib89","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104428_bib90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40364-020-00222-3","article-title":"Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia","volume":"8","author":"Yun","year":"2020","journal-title":"Biomark. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:39:51Z","timestamp":1728369591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":90,"alternative-id":["S1040842824001719"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104428","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104428"}}